Public finance of rotavirus vaccination in India and Ethiopia: An extended cost-effectiveness analysis

Vaccine

Volumn 31, Issue 42, 2013, Pages 4902-4910

  Verguet, Stéphane ^a   Murphy, Shane ^a   Anderson, Benjamin ^b   Johansson, Kjell Arne ^c   Glass, Roger ^d   Rheingans, Richard ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c UNIVERSITY OF BERGEN   (Norway)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Child health; Equity; Extended cost effectiveness analysis (ECEA); Financial risk protection; Low and middle income settings; Rotavirus; Vaccination

Indexed keywords

ROTAVIRUS VACCINE;

ARTICLE; CHILD; CHILD HEALTH CARE; CHILD HOSPITALIZATION; CHILDHOOD MORTALITY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; ETHIOPIA; EXTENDED COST EFFECTIVENESS ANALYSIS; FINANCIAL MANAGEMENT; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEALTH PROGRAM; HOUSEHOLD; HUMAN; IMMUNIZATION; INCOME; INDIA; MAJOR CLINICAL STUDY; MASS IMMUNIZATION; PRIORITY JOURNAL; RISK MANAGEMENT; ROTAVIRUS; ROTAVIRUS INFECTION; VACCINATION;

CHILD HEALTH; EQUITY; EXTENDED COST-EFFECTIVENESS ANALYSIS (ECEA); FINANCIAL RISK PROTECTION; LOW- AND MIDDLE-INCOME SETTINGS; ROTAVIRUS; VACCINATION;

CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; ETHIOPIA; FEMALE; HEALTH POLICY; HOSPITALIZATION; HUMANS; INDIA; INFANT; INFANT, NEWBORN; MALE; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; SURVIVAL ANALYSIS; VACCINATION;

EID: 84884205335     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.07.014     Document Type: Article

References (56)

1. Liu L., Johnson H.L., Cousens S., Perin J., Scott S., Lawn J.E., et al. Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet 2012, 379:2151-2161.
2. Tate J.E., Burton A.H., Boschi-Pinto C., Steele A.D., Duque J., Parashar U.D., et al. 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: as systematic review and meta-analysis. Lancet Infectious Diseases 2012, 12:136-141.
3. Morris S.K., Awasthi S., Khera A., Bassani D.G., Kang G., Parashar U.D., et al. Rotavirus mortality in India: estimates based on a nationally representative survey of diarrhoeal diseases. Bulletin of the World Health Organization 2012, 90(10):720-727.
4. Boom J.A., Tate J.E., Sahni L.C., Rench M.A., Hull J.J., Gentsch J.R., et al. Effectiveness of pentavalent rotavirus vaccine in a large urban population in the United States. Pediatrics 2010, 125:e199-e207.
5. Mwenda J.M., Mina Ntoto K., Abebe A.A., Enweronu-Laryea C., Amina L., Mchomvu J., et al. Burden and epidemiology of rotavirus diarrhea in selected African countries: preliminary results from the African Surveillance Network. Journal of Infectious Diseases 2010, 202(1):S5-S11.
6. Kahn G., Fitzwater S., Tate J., Kang G., Ganguly N., Nair G., et al. Epidemiology and prospects for prevention of rotavirus disease in India. Indian Pediatrics 2012, 49:467-474.
7. Patel M., Shane A.L., Parashar U.D., Jiang B., Geutsch J.R., Glass R.I. Oral rotavirus vaccines: how well will they work where they are needed most. Journal of Infectious Diseases 2009, 200(Suppl 1):S39-S48.
8. Nelson A.S., Glass R.I. Rotavirus: realizing the potential of a promising vaccine. Lancet 2010, 376:568-570.
9. Atherly D.E., Dreibelbis R., Parashar U.D., Levin C., Wecker J., Rheingans R.D. Rotavirus vaccination: cost-effectiveness and impact on child mortality in developing countries. Journal of Infectious Diseases 2009, 200(S1):S28-S38.
10. Atherly D.E., Lewis K.D.C., Tate J., Parashar U.D., Rheingans R.D. Projected health and economic impact of rotavirus vaccination in GAVI-eligible countries: 2011-2030. Vaccine 2012, 30S:A7-A14.
11. Kim S-Y., Sweet S., Slichter D., Goldie S. Health and economic impact of rotavirus vaccination in GAVI-eligible countries. BMC Public Health 2010, 10:253.
12. Podewils L.J., Antil L., Hummelman E., Bresee J., Parashar U.D. Economic costs of rotavirus gastroenteritis and cost-effectiveness of vaccination in developing countries. Journal of Infectious Diseases 2005, 192(S1):S133-S145.
13. Rheingans R.D., Antil L., Dreibelbis R.S., Podewils L.J., Bresee J.S. Economic costs of rotavirus gastroenteritis and cost-effectiveness of vaccination in developing countries. Journal of Infectious Diseases 2009, 200(Suppl. 1):S16-S27.
14. Tu H.A.T., Woerdenbag H.J., Kane S., Rozenbaum M.H., Li S.C., Postma M.J. Economic evaluations of rotavirus immunization for developing countries. Expert Review of Vaccines 2011, 10(7):1037-1051.
15. Bishai D., Koenig M., Khan M.A. Measles vaccination improves the equity of health outcomes: evidence from Bangladesh. Health Economics 2003, 12:415-419.
16. Rheingans R.D., Atherly D., Anderson J. Distributional impact of rotavirus vaccination in 25 GAVI countries: estimating disparities in benefits and cost-effectiveness. Vaccine 2012, 30S:A15-A23.
17. Banerjee A.V., Duflo E., Glennerster R., Khotari D. Improving immunisation coverage in rural India: clustered randomised controlled evaluation of immunisation campaigns with and without incentives. British Medical Journal 2010, 340:c2220.
18. rd edition, Working Paper No. 1 2012, University of Washington, Seattle, http://www.dcp-3.org/resources/universal-public-finance-tuberculosis-treatment-india-extended-cost-effectiveness-analysis (Accessed 17.07.13).
19. International Institute for Population Sciences (IIPS). District Level Household and Facility Survey (DLHS-3), 2007-08: India. IIPS: Mumbai, 2010.
20. Central Statistical Agency [Ethiopia] and ICF International. Ethiopia Demographic and Health Survey 2011. Central Statistical Agency and ICF International: Addis Ababa, and Calverton, Maryland; 2012.
21. World Health Organization, Department of Immunization, Vaccines and Biologicals. WHO guide for standardization of economic evaluations of immunization programmes. World Health Organization: Geneva; 2008.
22. United Nations Population Division. Department of Economic and Social Affairs. World Population Prospects: The 2010 Revision. United Nations: New York; 2011.
23. National Sample Survey Organisation. National Sample Survey Round 60. Ministry of Statistics and Programme Implementation. Government of India: New Delhi; 2004.
24. Nokes D.J., Abwao J., Pamba A., Peenze I., Dewar J., Maghenda J.K., et al. Incidence and clinical characteristics of Group A rotavirus infections among children admitted to hospital in Kilifi, Kenya. PLoS Medicine 2008, 5(7):e153.
25. Bahl R., Ray P., Subodh S., Shambharkar P., Saxena M., Parashar U.D., et al. Incidence of severe rotavirus diarrhea in New Delhi, India, and G and P types of the infecting rotavirus strains. Journal of Infectious Diseases 2005, 192(Suppl. 1):S114-S119.
26. Banerjee I., Ramani S., Primrise B., Moses P., Iturriza-Gomara M., Gray J.J., et al. Comparative study of the epidemiology of rotavirus in children from a community-based birth cohort and a hospital in South India. Journal of Clinical Microbiology 2006, 44(7):2468-2474.
27. Tate J.E., Chitambar S., Esposito D.H., Sarkar R., Gladstone B., Ramani S., et al. Disease and economic burden of rotavirus diarrhea in India. Vaccine 2009, 27S:F18-F24.
28. UNICEF. Management practices for childhood diarrhea in India. UNICEF: New Delhi; 2009.
29. Gladstone B.P., Ramani S., Mukhopadhya I., Muliyil J., Sarkar R., Rehman A.M., et al. Protective effect of natural rotavirus infection in an Indian birth cohort. New England Journal of Medicine 2011, 365:337-346.
30. Parashar U.D., Hummelman E.G., Bresee J.S., Miller M.A., Glass R.I. Global illness and deaths caused by rotavirus disease in children. Emerging Infectious Diseases 2003, 9(5):565-572.
31. World Bank Ethiopia: A country status report on health and poverty, Volume 2, Main Report. The World Bank: Washington, DC; 2005.
32. World Bank World Development Indicators. The World Bank: Washington, DC, 2012. Available at: (Accessed 20.11.12). http://data.worldbank.org/data-catalog/world-development-indicators.
33. Zaman K., Duc Ahn D., Victo J.C., Shin S., Yunus M., Dallas M.J., et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomized, double-blind, placebo-controlled trial. Lancet 2010, 376:615-623.
34. Madhi S.A., Cunliffe N.A., Steele D., Witte D., Kirsten M., Louw C., et al. Effect of rotavirus vaccine on severe diarrhea in African infants. New England Journal of Medicine 2010, 362(4):289-298.
35. Global Alliance for Vaccines and Immunization. (Accessed 13.09.12). http://www.gavialliance.org/.
36. Wolfson L.J. WHO immunization coverage estimates and trajectories (WHO ICE-T). Geneva: World Health Organization 2008, Department of Immunization, Vaccines and Biologicals.
37. Tate J.E., Cortese M.M., Payne D.C., Curns A.T., Yen C., Esposito D.H., et al. Uptake: impact, and effectiveness of rotavirus vaccination in the United States. The Pediatric Infectious Disease Journal 2011, 30(1):S56-S60.
38. Yen C., Guardado J.A.A., Alberto P., Rodriguez Araujo D.S., Mena C., Cuellar E., et al. Decline in rotavirus hospitalizations and health care visits for childhood diarrhea following rotavirus vaccination in El Salvador. The Pediatric Infectious Disease Journal 2011, 30(1):S6-S10.
39. Buttery J.P., Lambert S.B., Grimwood K., Nissen M.D., Field E.J., Macartney K.K., et al. Reduction in rotavirus-associated acute gastroenteritis following introduction of rotavirus vaccine into Australia's national childhood vaccine schedule. The Pediatric Infectious Disease Journal 2011, 30(1):S25-S29.
40. McClellan M., Skinner J. The incidence of medicare. Journal of Public Economics 2006, 90:257-276.
41. Smith P.C. Incorporating financial protection into decision rules for publicly financed healthcare treatments. Health Economics 2013, 22:180-193.
42. Pratt J.W. Risk aversion in the small and in the large. Econometrica 1964, 32(1):122-136.
43. Arrow K.J. Aspects of the theory of risk bearing 1965, Academic Bookstores, Helsinki.
44. Wolfram Research, Inc., Mathematica, Version 8.0, Champaign, IL, 2010.
45. Bharat biotech to supply rotavirus vaccine at $1. (Accessed 13.09.12). http://articles.economictimes.indiatimes.com/2011-06-06/news/29625806_1_rotavirus-vaccine-pentavalent-vaccine-conjugate.
46. Kruk M.E., Goldmann E., Galea S. Borrowing and selling to pay for health care in low- and middle-income countries. Health Affairs 2009, 28(4):1056-1066.
47. Banerjee A.V., Duflo E. The economic lives of the poor. Journal of Economic Perspectives 2007, 21(1):141-167.
48. Armah G.E., Sow S.O., Breiman R.F., Dallas M.J., Tapia M.D., Feikin D.R., et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis infants in developing countries in sub-Saharan Africa: a randomized, double-blind, placebo-controlled trial. Lancet 2010, 376:606-614.
49. Phua K.B., Lim F.S., Lau Y.L., Nelson E.A.S., Huang L.M., Quak S.H., et al. Safety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: randomized, double-blind, controlled study. Vaccine 2009, 27:5936-5941.
50. Vesikari T., Itzler R., Matson D.O., Santosham M., Christie C.D.C., Coia M., et al. Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated health care utilization across three regions (11 countries). International Journal of Infectious Diseases 2007, 11(Suppl. 2):S29-S35.
51. Pitzer V.E., Viboud C., Simonsen L., Steiner C., Panozzo C.A., Alonso W.J., et al. Demographic variability, vaccination, and the spatiotemporal dynamics of rotavirus epidemics. Science 2009, 325:290-294.
52. Pitzer V.E., Atkins K.E., de Blasio B.F., Van Effelterre T., Atchison C.J., et al. Direct and indirect effects of rotavirus vaccination: comparing predictions from transmission dynamic models. PloS ONE 2012, 7(8):e42320.
53. Deogaonkar R., Hutubessy R., van der Putten I., Evers S., Jit M. Systematic review of studies evaluating the broader economic impact of vaccination in low- and middle-income countries. BMC Public Health 2012, 12:878.
54. Bärnighausen T., Bloom D.E., Canning D., Friedman A., Levine O.S., O' Brien J., et al. Rethinking the benefits and costs of childhood vaccination: the example of Haemophilus influenza type b vaccine. Vaccine 2011, 29:2371-2380.
55. Stack M.L., Ozawa S., Bishai D.M., Mirelman A., Tam Y., Niessen L., et al. Estimated economic benefits during the 'Decade of Vaccines' include treatment savings, gains in labor productivity. Health Affairs 2011, 30:1021-1028.
56. Ozawa S., Stack M.L., Bishai D.M., Mirelman A., Friberg I., Niessen L., et al. During the 'Decade of Vaccines' the lives of 6.4 million children valued at $231 billion could be saved. Health Affairs 2011, 30:1010-1020.